



Abstract—Over 60% of deaths in the world are due to non-
communicable diseases (NCDs), principally referring to 
cardiovascular diseases, diabetes, cancer and chronic respiratory 
disease. Nearly 80% of these NCD deaths occur in low- and 
middle-income (LMIC) countries, where it is difficult for people 
to access essential medicine for treatment. The problem of 
effective access results in part from the exorbitantly high prices 
that arise from the negative effects of global patent protection. 
The WTO Trade-Related Aspects of Intellectual Property Rights 
Agreement (TRIPS) offers flexibilities, such as compulsory 
licenses and parallel importing, to remedy those negative effects.  
Hence, two fundamental questions arise. To what extent do 
LMIC countries benefit from these safeguards when it comes to 
providing essential medicines for their populations?  What 
options and political barriers do these countries have when 
making the case for being able to make NCD essential medicines 
accessible to their populations, and what lessons can be learned 
from the successes of increased and affordable access to 
AIDS/HIV medicines from the early 2000s?  Through 
introspection of emerging case studies, this article explores ways 
to reduce barriers to essential medicines for NCDs under the 
WTO TRIPS frameworks and other relevant regulations related 
to pharmaceutical trade and patents.   
 
Index Terms—Noncommunicable Disease, TRIPS Agreement, 




ccording to the World Health Organization, 63 percent 
of 57 million global deaths in 2008 resulted from NCDs, 
which principally refer to cardiovascular diseases, diabetes, 
cancer and chronic respiratory disease. NCDs are estimated to  
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impose a cumulative output loss of US$ 47 trillion till 2030, 
which is equivalent to 75% of global GDP in 2010 (Bloom, 
Cafiero, et al. 2011). This loss also represents enough money 
to eliminate 1.25 dollar-a-day extreme poverty among the 1.29 
billion people for more than half a century. 
The economic burden of NCDs on developing countries is 
significant.  A report of US Institute of Medicine suggested 
that the economic impact of cardiovascular diseases (CVD) 
and related chronic diseases, such as diabetes and chronic 
obstructive pulmonary disease (COPD) ranged from an annual 
US$ 3 billion for direct medical costs of obesity-related 
diabetes, coronary heart disease, hypertension and stroke in 
China to US$ 72 billion for treatment of and productivity 
losses due to five chronic conditions in Brazil (Bloom, 
Cafiero, et al. 2011). 
NCDs are also imposing a heavy toll on individuals and 
national productivity.  For most patients suffering from NCDs 
in developing countries, the exorbitantly high prices of 
medicines and out-of-pocket healthcare treatment expense trap 
people in poverty. In addition, because NCDs are having an 
impact on younger generations, who comprise most of the 
working class in developing countries, national productivity is 
at risk.  For instance, 25% of people between 18 – 59 years 
old in Ukraine have at least one NCD, which made could 
result in ‘Losing the next generation to chronic diseases’ (The 
World Bank, the Ukrainian Medical Alliance, 2010). 
In terms of the heavy toll seen in LMICs, there has also 
emerged a trend known as the ‘double burden’, or ‘double 
jeopardy’.  This trend essentially refers to the simultaneous 
prevalence of NCDs alongside communicable disease 
prevalence in low-income countries. In 2002 NCDs accounted 
for 44 percent of the total death burden. Projections show that 
by 2030 the share of the death burden for NCDs in LMICs 
will be 54 percent while the share for communicable diseases 
will be reduced to 32 percent of all deaths (Figure 1) 
(Department of State and the Department of Health and 
Human Services , 2007). 
 
Implications of TRIPS Flexibilities for Access 
to Non-communicable Disease Medicines in 
Lower and Middle Income Countries  
 
Saba Danawala and Zoe Zhang 
A
       DOI: 10.5176/2345-718X_1.1.1 
GSTF International Journal of Nursing and Health Care (JNHC) Vol.1 No.1, October 2013




Fig 1: 2002 and 2030 Projections for Share of Communicable 
and Noncommunicable Diseases 
Source: Lopez et al., 2006 
Limited access to NCD essential medicines is one of the 
barriers to treatment as well as controlling progression of 
certain NCDs.  There are many reasons for lack of access to 
essential medicines, but the high prices of drugs often stem 
from strong intellectual property protections. Governments in 
developing countries that attempt to lower the price of 
medicines have come under pressure from industrialized 
countries and the multinational pharmaceutical industry.  
Therefore, this paper is mainly focusing on the treatment 
problems as they are related to access around essential 
medicines for treatment in LMICs.  Based upon the World 
Health Organization (WHO) definition of essential medicines, 
the term refers to ‘…those [medicines] that satisfy the priority 
health care needs of the population’ and is based on the 
following criteria: disease prevalence, evidence on efficacy 
and safety, and comparative cost-effectiveness (World Health 
Organization, 2011). 
Due to the low cost and potential benefits of preventing 
NCDs, national and international communities have already 
been engaging in advocacy efforts that promote the reduction 
of the NCDs risk factors, which include tobacco use, physical 
inactivity, unhealthy diet and the harmful use of alcohol. The 
reduction of these risk factors falls into the public health 
category of primary prevention. Still, compared with the 
primary prevention strategy, NCD treatment receives less 
attention because of the relatively high cost and health systems 
capacity to treat.  As Secretary-General of the United Nations, 
Ban Ki-moon, stated during the High-level Meeting of the 
General Assembly on the Prevention and Control of 
Noncommunicable Diseases in September 2011, ‘treating the 
NCDs could be affordable, while preventing them could cost 
next to nothing, and even save money’ (United Nation General 
Assembly GA/11138, 2011). 
Thus far, low public sector availability of NCD essential 
medicines is often due to lack of public resources or under-
budgeting, inaccurate demand forecasting, and inefficient 
procurement and distribution. This is the point where 
government and patients turn to the private sector in order to 
access generic medicines, which are often 2-3 times more 
expensive.  These high prices are mostly due to high 
manufacturer’s prices secondary patent protections, taxes and 
tariffs, and high mark-ups in the supply chain (WHO Essential 
Medicines Briefing Document, 2011).  Besides the barrier 
posed from patents in the private sector, many low-income 
countries do not have the local infrastructure and capacity for 
innovative research and development for pharmaceuticals.  In 
contrast, middle-income countries are able to reproduce 
generic medicines at cheaper prices with the same active 
ingredients that are currently established for medications.   
The essential medicine needs around the global burden of 
NCDs, calls for a broader perspective and scope of public 
health policy frameworks as they relate to international 
pharmaceutical products and trade. The first major framework 
is the international legal cornerstone of intellectual property, 
the TRIPS agreement and the WTO debates around it. The 
second is current free trade and regional trade agreements that 
act as extensions and implementation mechanisms, or, in some 
cases, contradictions of TRIPS. 
 
I. TRIPS AND THE INTELLECTUAL PROPERTY REGIME 
 
The Trade-Related Aspects of Intellectual Property 
Rights (TRIPS Agreement) was drafted during the creation of 
the World Trade Organization (WTO) in 1995.  TRIPS set out 
to establish a common global standard for the protection of 
intellectual property rights, including patents (Beall & Kuhn, 
2012).  Indeed, agreement to TRIPS is often described as a 
package deal whereby developing countries acceded to TRIPS 
requirements in exchange for other benefits of WTO 
membership, including increased access to foreign markets. 
One cannot talk about TRIPS without also understanding 
the Doha Declaration on Public Health from 2001.  Although 
the statements that were made on public health under the Doha 
Declaration do not have the same legal clout as TRIPS, these 
statements have played a major role in framing the way TRIPS 
should be interpreted and how the terms discussed in it should 
be defined (Backhoum, LLM, 2008).  In order to reduce the 
inequality in essential medicine access between the developing 
and developed countries, the declaration included protective 
provisions to address public health concerns. 
These protective provisions established the following tools: 
compulsory licenses and parallel imports, both of which are 
considered as TRIPS flexibilities. The third tool, differential 
pricing, is looser and is not used as much of a bargaining chip 
or threat as the other two, but is still a major part of affordable 
access to essential medicines. Aside from the legal statements 
and WTO discourse behind these tools, one should also pay 
attention to the way countries used the tools as forms of 
negotiation. For this reason, this section provides an overview 
of these tools through a review of the articles in TRIPS, in 
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conjunction with disputes around these tools that were argued 
before the WTO. 
First, there are compulsory licenses, which were officially 
introduced in TRIPS Article 31.  This article recognized the 
right of member states to invoke compulsory licenses for 
different types of patents, including pharmaceuticals. 
Compulsory licenses are a provision in which ‘governments 
allow someone else to produce the patented product or process 
without the consent of the patent owner’ (World Trade 
Organization, 2006). However, the problem mainly lies in 
which medicines should be listed under the compulsory 
license and how. At the same time TRIPs also limited 
compulsory license action by requiring a period of negotiation 
between the member state and the patent holder.  The 
exception to this negotiation, however, as noted in 
subparagraph (b), is if there is a ‘case of a national emergency 
or other circumstances of extreme urgency' (Sinhaya, 2012). 
In 2001, around the time of the Doha Rounds, Article 31 
came into question in regards to public health. In terms of an 
actual public health ‘emergency’, the Doha Declaration on 
TRIPS and Public Health confirms that countries are free to 
determine the grounds for granting a tool known as 
compulsory licenses.  Hence, the Doha Declaration has not 
fully defined when compulsory licenses are actually valid to 
use, which has shown to be controversial as this paper later 
discusses with the case studies from India and Thailand.  
Another barrier with Article 31(f) of the TRIPS Agreement is 
the restriction that compulsory licensing is valid 
‘predominantly for the supply of the domestic market of the 
member authorizing such use’. This means that a country 
making use of a compulsory license must manufacture the 
product locally for the domestic market.  Clearly, such an 
assumption takes for granted that the country has sufficient 
local manufacturing capacity, which is not the case for many 
LMICs (Sinhaya 2012). 
As a result of these barriers, the WTO granted TRIPS 
waivers.  The first waiver said that exporting countries’ 
obligations under Article 31(f) are waived.  This means that 
any member country can export generic pharmaceutical 
products made under compulsory licenses to importing 
countries that have a need for their populations.  The second 
waiver addressed remuneration to the patent holder, stating 
that importing countries were not obligated to compensate in 
order to avoid double payment. Remuneration is only required 
on the export side. The final waiver was a vague. The waiver 
stated generally that exporting constraints would be waived 
for developing and least developed countries. This was done 
in order to allow for these countries to export within a regional 
trade agreement, when at least half of the members were 
categorized as least-developed countries at the time of the 
decision (World Trade Organization, 2006). 
Another aspect of the waiver negotiations that was debated 
was the scope of diseases covered by TRIPS waivers.  This is 
especially important for the scope of this paper and for the 
urgency of essential medicine access for NCDs in LMICs. The 
United States called for limitations of the waivers to 
HIV/AIDS, malaria, tuberculosis ‘and potentially a small 
group of others infectious diseases’.  The European Union, 
was not as specific, but rather very vague and, “proposed that 
the solution be confined to ‘grave’ public health problem”.  
LMICs adopted an unrestricted approach regarding the scope 
of diseases (Backhoum, LLM 2008). 
The second tool in consideration of TRIPS flexibilities is 
parallel importing, which, in short, allows countries to import 
a product made legally abroad without the permission of the 
intellectual property right holder, such as the patent or 
trademark holder (World Trade Organization, 2006).  
Understanding the tool at its best requires understanding how 
it has actually been used.  The HIV/AIDS epidemic was at its 
most critical point during the inclusion of parallel imports in 
TRIPS.  Civil society and international advocacy groups in 
LMICs were putting pressure on their governments to reform 
access to HIV medications.  The case that set the precedent for 
questioning the validity of the parallel importing tool under 
TRIPS was in South Africa in April 2001.   
The South African government had previously passed the 
‘Medicines and Related Substances Control Amendment Act’ 
in 1997.  This law made medicines more affordable by 
allowing parallel imports, enforcing generic substitution, and 
implementing price controls.  The Pharmaceutical Industry 
Association and 39 of its affiliate pharmaceutical companies 
sued the Government of South Africa regarding provisions of 
this act.  These parties argued that the law was 
unconstitutional and violated the TRIPS Agreement (Medicins 
Sans Frontieres/Doctors Without Borders, 2001). 
Public protests in South Africa and neighboring African 
countries focused on access to antiretroviral treatment.   The 
cost of patented medicines was, at the time, the main obstacle 
to bringing life-saving treatment to South Africa's 4.7 million 
people living with HIV/AIDS.  In terms of the actual way in 
which the South African Government defended its legislation 
as constitutional, it argued two major grounds.  First, it argued 
that it did not abrogate any patent rights.  Second, it stated that 
section 15C complied with TRIPS, arguing that TRIPS did 
not, after all, prohibit parallel imports.  With the South African 
parallel importing case in consideration, WTO members 
realized that they needed to come to a consensus on the issues 
around exports and imports of pharmaceuticals.  The legal 
problem for exporting countries was resolved in August 2003 
when WTO members reached an agreement to make it easier 
for countries to import cheaper generics made under 
compulsory licensing if they have little capacity to 
manufacture the medicines themselves (Fisher & Rigamonti 
2005).  
The third tool for TRIPS discourse is differential pricing, 
which proponents defend as a more viable and politically 
feasible option.  Although WTO member nations conducted a 
workshop in 2001, when TRIPS was being debated in general 
and in the context of the Doha Declaration on Public Health, 
the research and discussion for differential pricing still 
continues.  In the context of pharmaceutical and other health 
products, differential pricing is the adaptation of product 
prices based on the purchasing power of consumers in 
different geographical or socio-economic segments (Yadav 
2010). Still, even with the support of differential pricing in 
theoretical models, the differential pricing mechanisms across 
pharmaceutical products are not always equal.    
Historically, the pharmaceutical industry had been cautious 
of extending low prices for a large number of drugs in low-
income markets due to the fear of eroding profit margins in 
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high- and middle-income markets (Yadav 2010).  While there 
are many differential pricing models, one suggestion that 
Yadav puts forth in his WHO paper is that pharmaceutical 
firms could use the model of intra-country differential pricing.  
This means that different socio-economic segments of the 
population in LMICs seek treatment and obtain medicines 
from different channels, with wealthier patients seeking 
treatment in channels different from their poorer counterparts. 
One example of this ‘intra-country’ method is Novartis’ 
segmentation strategy by public and private sector for the 
malarial treatment drug, Coartem (Figure 2) (Yadav 2010). 
 
Fig 2: Novartis’ Intra-country Differential Pricing for Coartem 
Source: Novartis 2009 
 
A final point that, while not in the scope of this paper, is the 
current barriers that are now posed by the emergence of 
discussions on TRIPS Plus. TRIPS Plus is not necessarily a 
‘formal agreement’, and is beyond the scope of the original 
TRIPS Agreement.  It rather is a loose concept that is referring 
to: 
 
…the adoption of multilateral, plurilateral, regional 
and/or national intellectual property rules and practices 
which have the effect of reducing the ability of developing 
countries to protect the public interest aims to increase 
the level of protection for right holders beyond that which 
is given in the TRIPS Agreement... (Musungu & Dutfield 
2003). 
 
So far, these rules have been in the context of bilateral free 
trade agreements (FTAs), of which two major ones are the 
Thailand and South African Customs Union (SACU) FTAs.  
When moving forward in the discussion of advocating for 
affordable access to NCD medications in LMICs, the 
restrictions of patents imposed by these FTAs are important.  
They represent new challenges taking place as a result of the 
end of flexible patent regulations that ended for middle-
income countries, which have some pharmaceutical 
manufacturing capacity. 
II. FOUNDATIONS FOR MAKING THE CASE FOR NCD 
ESSENTIAL MEDICINE ACCESS TO  TRIPS GOVERNING BODIES 
International health attention, on both social and economic 
terms, has traditionally focused on communicable diseases, 
such as tuberculosis, polio, and HIV/AIDs.  The first 
statement in the Doha Declaration on TRIPS Agreement and 
Public Health, the statement reads as follows: 
We recognize the gravity of the public health 
problems afflicting many developing and least-
developed countries, especially those resulting from 
HIV/AIDS, tuberculosis, malaria and other 
epidemics, (World Trade Organization Declaration 
on TRIPS and Public Health, 2001). 
What remains vague here is how the declaration defines the 
‘other epidemics’ part of the statement.  There is particular 
emphasis over the three most devastating communicable 
diseases, but there seems to be no consensus as to what 
constitutes an epidemic.  The word is instead left up to 
interpretation.  This presents a unique question now that 
NCDs have moved to the international forefront.  In 
September 2011, the United Nations hosted a two-day meeting 
on NCDs.  It was only the second UN High Level Meeting 
(UNHLM) that was based upon a health issue.  The first high-
level meeting focused on HIV/AIDS in 2001 (Bollyky, 2011). 
For NCDs, the mortality statistics certainly speak to the 
urgency of the situation, but how to actually create measurable 
targets to reduce their burden was something the UNHLM 
addressed.  Princess Dina Mired, who spoke on behalf of the 
Union for International Cancer Control at the introduction of 
the high-level meeting, pointed out that: 
 
[While the UN Declaration] noted that chronic 
diseases were a great equalizer among the rich and 
poor, the Declaration failed to recognize that the 
burden of those diseases was an epidemic, (United 
Nation General Assembly GA/11138, 2011). 
 
She stressed that NCDs needed to be labeled adequately and 
appropriately, and not simply as ‘a [watered-down] problem of 
epidemic proportions’ (United Nation General Assembly 
GA/11138, 2011).  She also stated that the Political 
Declaration on NCDs lacked clear and measurable targets.  To 
the credit of the declaration, Paragraph 45 specifies the usage 
of TRIPS flexibilities to the fullest.  Paragraph 52 says that 
international organizations should provide technical assistance 
and capacity to developing countries in areas of NCD 
prevention and control, as well as, promote access to 
medicines (United Nations General Assembly A/66/L.1, 
2011).  Still, the lack of targets points to the idea that 
international organizations have not discussed the burden of 
NCDs with the same types of tangibility as HIV/AIDS.  One 
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major reason for this gap is a misconception of ‘emergency’ 
taking precedence over the term ‘epidemic’.  Pharmaceutical 
industries have disseminated this misconception publicly and 
have used it, for example, to restrict when compulsory licenses 
can or cannot be used (Abbott, 2011).  This has very narrowly 
limited the scope of pharmaceutical patents as they relate 
public health issues to just the HIV/AIDS issue.   
Hence, this was the major reason why the high-level 
meeting was needed and targets needed to be set.  
Interestingly, among those targets, Princess Dina mentioned 
essential medicines (Abbott, 2011).  In regards to the mention 
of TRIPS in the 2011 NCD UNHLM, Liow Tion Lai, Minister 
of Health of Malaysia emphasized major issue with TRIPS.  
He drew upon the United Nations Declaration on HIV/AIDS, 
which had endorsed the use of ‘flexibilities’ guaranteed by 
WTO TRIPS in order to address that trade did not trump the 
right of patients.  Using this precedent, he emphasized that 
Malaysia, like many countries were challenged to provide 
access to essential medicines to manage NCDs and, for 
Malaysia, generic drugs were essential to delivering health 
care to its people (United Nation General Assembly 
GA/11138, 2011).  In other words, to have TRIPS as a barrier 
in the case of NCDs would be counteractive for developing 
countries, which are already lacking in health systems and 
infrastructural resources. 
Fortunately, since the high-level meetings, the World 
Health Organization (WHO) has been circulating discussion 
papers between member state stakeholders from a working 
group.  So far, in response to paragraph 8 of the World Health 
Assembly decision WHA65(8), the WHO Secretariat has the 
responsibility of developing a revised WHO Discussion Paper 
on a global NCD monitoring framework that includes 
indicators and a set of voluntary global targets both for 
prevention and control of NCDs.  WHO regional committees 
have finished their meetings, and a formal meeting took place 
between member states in November 2012.  The draft report at 
that meeting has listed 11 ‘targets’ to be addressed by 2025.  
There are three categories of targets: (1) outcome targets 
(premature mortality rate reduction), (2) exposure targets (i.e. 
alcohol use, fat intake, obesity, etc.), and (3) health systems 
response targets.  In the third category, there are two targets, 
both of which deal with NCD drug treatments and 
medications.   
One target requires that ‘50% of eligible people receive 
drug therapy to prevent heart attacks and strokes, and 
counseling’.  The other requires ‘80% availability of basic 
technologies and generic essential medicines required to treat 
major NCDs in both public and private facilities’ (World 
Health Organization NCD Discussion Paper 2012).  The 
indication of these two targets as health systems responses 
speaks to Lai’s point, and therefore, gives preliminary 
international legitimacy and attention to the need for 
facilitating affordable access to NCD essential medicines and 
drug treatments.  However, a question remains, at least with 
regards to TRIPS flexibilities and where patents are a concern.  
Which NCD-based patent drugs are actually needed to provide 
effective treatment and to what extent are patents a problem 
(Abbott, 2011)?  This is something these targets need to 
address, rather than just a vague idea of availability, in order 
for the essential medicine targets to have some legitimacy in 
TRIPS and WTO-related discussions. 
Given how new the international discourse on NCD 
essential medicine access is, it is crucial to see what insights 
LMICs can adopt from the HIV/AIDS case.   Besides the 
international pressure and attention in South Africa, Brazil 
presented a case of being able to ‘fight back’ economically.  
Simultaneously, with the 2001 South African battle over the 
exorbitant price of HIV/AIDS drugs, as previously explained, 
Brazil purchased two patented HIV/AIDS drugs, efavirenz and 
nelfinavir, both of which are sold in the U.S. for more than 
US$ 4,000 per patient.  In short, Brazil made these drugs 
available at no cost to its own population, and threatened to 
allow its local pharmaceutical companies to manufacture 
generic versions of the medicines if the prices were not 
reduced.  After seven months of unsuccessful negotiations, the 
United States, on 8 January 2011, asked the WTO to form a 
dispute settlement panel regarding Brazilian patent law.  
Essentially, the U.S. was not successful in this proceeding 
when Brazil threatened to use a compulsory license per its 
own laws, and the U.S. was compelled, to a great degree by 
international pressure, to withdraw its complaint against Brazil 
in the WTO on 25 June 2001 (Thomas, 2001). 
Therefore, a major part of the general HIV/AIDS 
pharmaceutical access story was the use of compulsory 
licenses for antiretroviral (ARV) medications, or in Brazil’s 
case, the threat of using compulsory licenses.   Between 2001 
and 2010, 24 compulsory licensing episodes in 17 countries 
were reported, based on a recent database analysis by Beall 
and Kuhn.  Most of the compulsory license episodes involved 
drugs for HIV/AIDS, with a few for ‘other communicable 
diseases’, and five cases involving drugs for NCDs, such as 
cancer.  These five cases were only in Thailand and India, 
which are further discussed in the case studies section (Figure 
3) (Beall & Kuhn 2012).  The authors concluded that: 
…the barriers to compulsory license use in LDCs 
and low- income countries go well beyond the lack of 
production capacity, and likely extend to health 
system incapacity, political pressure against 
compulsory licenses, and the legislative difficulties of 
issuing a compulsory license, (Beall & Kuhn 2012).   
The authors may have a point because the case for NCD 
medications, though still very new, may face new limitations 
and challenges as delineated above.  It will be interesting to 
see what current and new methods and measures LMICs will 
or will not employee under TRIPS provisions in order to 
advocate for NCD essential medicines at an affordable price.  
This is further explored in the following section of case 
studies. 
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Fig 3: Distribution of Compulsory License Cases by WTO 
Outcome, Disease Group, and Income 
 
Source: Beall and Kuhn 2012 
III. CASE STUDIES 
 
For a better view on LMICs’ current use of TRIPS 
flexibilities and obstacles, this section provides several case 
studies on specific developing countries to investigate the 
effectiveness, feasibility and potential risks when using TRIPS 
flexibilities, mainly compulsory licenses, for better access to 
NCD treatment.  The only two countries that have so far 
issued compulsory licenses on NCD drugs, Thailand and 
India, illustrated the effectiveness of using TRIPS flexibilities 
to drive down high prices of patented NCD drugs.  This was 
true even though both countries received various international 
responses, including opposition from the pharmaceutical 
industry and developed countries led by the US.   
Although China is an example of a middle-income 
developing country with a pharmaceutical manufacturing 
capacity, it has not issued any compulsory license for any 
drugs.  This illustrates the obstacles and concerns middle-
income countries have before issuing compulsory licenses. 
The last case study is about the use of TRIPS flexibilities in 
Sub-Saharan African region, where most countries are 
suffering from the disease double burden.  Some Sub-Saharan 
African countries, as the representative low-income countries, 
have issued compulsory licenses on HIV/AIDs drugs during 
the past decades.  The Sub-Saharan African case studies 
explore the implication of extending the use of compulsory 
licenses on NCDs in Sub-Saharan Africa and discuss the 





With the increased economic development and living 
standards during the past three decades, Thailand has made 
several achievements in the public health sector. Although 
HIV/AIDs is still one of the country’s major health problems, 
the prevalence rates of other communicable diseases have 
declined.  For instance, the mortality rate of Malaria decreased 
from 10.9 per 100,000 persons in 1977 to 0.1 per 100,000 
persons in 2009 (Wibulpolprasert, 2010).  However, with the 
environmental factors of changing lifestyle, urbanization and 
international trade, Asian countries, including Thailand, are 
seeing an increase in NCD risk factors.  According to the 
WHO, NCDs are estimated to account for 71% of all deaths in 
Thailand (World Health Organization, 2011). Therefore, a 
shift in public health has taken place from a strong focus on 
communicable diseases to NCDs. 
In order to address the urgent NCD problems in Thailand, 
the Thai government emphasized the prevention and control of 
NCD risk factors, as well as the need to pay attention to 
effective treatment of NCDs. One of the measures for NCD 
treatment is to issue a compulsory license to local 
pharmaceutical manufacturers to drive down the high price of 
NCD medicines. So far, the Thai government has issued seven 
compulsory licenses, of which two were antiretroviral, one 
was for heart disease and four were for cancer treatment 
(Wibulpolprasert, 2010). The issuance of compulsory licenses 
has driven down the prices for those medicines dramatically, 
making them more affordable and available to more patients in 
Thailand. 
The Thai government has formed its own patent laws in 
accordance with Article 31 of the TRIPS Agreement to 
authorize compulsory licenses and government use of patents 
on any patented drugs under two circumstances.  According to 
Section 51 of the Patent Act of Thailand, any ministry, sub-
ministry, or department of the Thai government can issue a 
compulsory license. The second circumstance under which a 
compulsory license can be issued is by the Prime Minister 
with the Cabinet’s approval during a state of war or 
emergency, in accordance with Section 52 (Wibulpolprasert, 
2010). 
In 2007, Thailand issued a compulsory license on Plavix for 
the treatment of cardiovascular diseases. It was considered 
significant not only because cardiovascular disease is one of 
the top causes of deaths, but also because it was the first 
compulsory license issued to a NCD medicine in Thailand. 
The compulsory license on Plavix reduced the price from US$ 
2.75 per tablet to US$ 0.03 per tablet (Wasserman, Priest. 
2012). Since 2008, four other drugs for cancer treatment have 
been granted compulsory licenses. The five compulsory 
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licenses on NCDs drugs have created a new controversy since 
the case of HIV/AIDS. Pharmaceutical industries opposed to 
the issuance of compulsory licenses argued that compulsory 
licenses denied the patent right to the innovator and 
discouraged pharmaceutical companies from further R&D. In 
2007, The United States Trade Representative placed Thailand 
on its ‘Special 301’ Report Priority Watch List, criticizing 
Thailand’s deficiency in IPR protection and the lack of 
transparency and due process during the issuance of 




India is the third largest pharmaceutical producer by volume 
in the world, but like other middle-income countries, it is also 
suffering from NCDs.  In 2004, 4.8 million of the estimated 
8.1 million Indian deaths were due to NCDs.  In 2004, out of 
pocket health care expenses amounted to 3.3 percent of India’s 
GDP, among which the share of NCDs increased from 31.6 
percent in 1995 to 47.3 percent in 2004.  If NCDs were 
completely eliminated, the estimated GDP in a year such as 
2004 would have been 4-10 percent higher (Mahal, Karan, 
Engelgau 2010). 
One of barriers in the battle against NCDs in India is the 
difficult access to expensive patented drugs for patients.  India 
is the fourth largest generic drug producer and globally ranks 
thirteenth in generic drug consumption. India’s generic drug 
industry provides 95% of its domestic medical needs (TATA 
Strategic Management Group, 2008). The price of generic 
drugs is usually a small fraction of the price of patented 
branded drugs.  Still, with NCDs accounting for the major 
cause of death in India, people need more affordable and 
reliable NCD drugs. 
India has a long history of including compulsory license in 
its legal system since 1970. Under Section 84 of the Patent 
Act 1970, any person can apply for compulsory license three 
years from the expiration date of a patent approval.  The 
Government of India allows this given the following 
circumstances: the patented invention does not satisfy the 
reasonable requirement of the public; the patented invention is 
not available to the public at a reasonable price.  After joining 
the WTO and the TRIPs Agreement in 1995, India amended 
its Patent Act 1970 three times in 1999, 2002, and 2005, 
respectively, to meet the standard of intellectual property 
rights protection.  For instance, the amendment expanded the 
introduction of product patents in the areas of chemicals, 
pharmaceuticals, agricultural chemicals, and food, which was 
not allowed under Patent Act 1970 (Kurian, 2011).   
In response to TRIPs flexibilities that give LMICs an 
extended period of time to fully comply with TRIPS 
requirement, India further allowed the granting of compulsory 
licenses on patented pharmaceutical exports to countries 
lacking manufacturing capacity under the 92A of Patent Act 
2005.  Doing this would help countries lacking such capacity 
address public health problems, assuming the country allows 
the importation from India. 
In March 2012, India issued its first NCD compulsory 
license to its domestic generic drug producer, Natco, which 
ended the monopoly of German pharmaceutical company 
Bayer-AG in anti-cancer medicine.  Natco suggested selling 
the drug ‘sorafenib tosylate’ at US$ 162 per patient per month, 
which lead to a 97 percent price cut compared to Nexavar, 
produced by Bayer-AG of US$ 5162.51 (Kurian, 2011).  The 
Indian government grants the compulsory license till 2020.  
Natco is not entitled to export the drug or to outsource its 
production. In addition, Natco must pay royalties to Bayer on 
a quarterly basis at the rate of 6 percent of the net sales of the 
medicine.  
International NGOs, such as Médecins Sans Frontières’, 
welcomed the use of compulsory licenses, arguing that it 
offered hope to patients.  It also showed that compulsory 
licenses could serve as a means of providing life-saving drugs 
under patent at a low price, while patent holder receive their 
royalties. This success has positive implications for drug 
access not only for Indian patients, but also for patients 
suffering from NCDs around the world. Nonetheless, 
developed countries led by the United States heavily criticized 
India for issuing a compulsory license on an anti-cancer 
generic drug, sorafenib tosylate (Silverman, 2012; ICTSD, 
2012). 
In January 2013, the Department of Pharmaceuticals under 
the Government of India decided to issue compulsory licenses 
for three more patented cancer drugs.  These are trastuzumab 
for breast cancer, ixebepilone for chemotherapy, and dasatinib 
for leukemia.  Trastuzumab is marketed under the 
pharmaceutical company Roche as Herceptin, while 
ixabepilone and dasatinib are marketed under Bristol-Myers 
Squibs as Ixempra and Sprycel, respectively.  Trastuzumab, 
ixabepilone and dasatinib currently cost approximately US$ 
810, US$ 1135-1300, and US$ 245, respectively, for a 
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projections yet regarding how much the price would be 
reduced.  However, this development shows a significant shift 
towards the Government of India’s efforts to address its 
growing cancer burden, which reflects a paradigm shift in the 
question of what constitutes a public health emergency. 
However, the Natco compulsory license) does not allow the 
exporting sorafenib tosylate.  This may also be most likely the 
case for the licenses for the three most recent cancer drugs.  
India, as the largest provider of cheap medicines is able to 
export its generic drugs to other countries, especially low-
income countries, based on the Indian domestic Patent Act 
2005 and TRIPS flexibilities (Bajaj, Pollack, 2012).   
The implication of exporting affordable generic drugs from 
middle-income countries to low-income countries is twofold. 
For middle-income countries, exporting generic drugs can 
expand their pharmaceutical markets, both domestically and 
abroad.  For low-income countries, importing generic drugs 
can solve the problem of lacking pharmaceutical 
manufacturing capacity, while providing patients with 
affordable access to NCD drugs.  Although no generic drugs 
for NCDs have been exported from middle-income countries 
to low-income countries so far, there are several examples for 
HIV/AIDS generic drugs already. For instance, in 2005, 
Ghana issued a government use compulsory license for 
importing Indian generic HIV/AIDS medicines (Ghana 
Ministry of Health, 2005).  This example shows the feasibility 




NCDs account for over 80 percent of 10.3 million annual 
deaths (Wang, Kong, Wu, Bai, and Burton. 2005). Based on a 
World Bank estimate, the economic benefit of reducing 
Cardiovascular Disease mortality by 1 percent per year over a 
30-year period could generate an economic value of 68 
percent of China’s GDP in 2010, more than US$ 10.7 trillion 
(Wang, Marquez, Langenbrunner, 2011). However, China is 
largely dependent on the imported patented drugs that are 
barely affordable for patients, due to the lack of research and 
development in the domestic pharmaceutical industry (Huang, 
2012). 
However, as a middle-income country that is also seriously 
affected by NCD problems, China has taken a different 
approach from Thailand and India. Rather than utilizing 
TRIPS flexibilities for NCD treatment, China has taken 
advantage of bilateral price negotiations with pharmaceutical 
companies to reduce the price for NCD patented drugs.  CFR 
Senior Fellow Yanzhong Huang argued that in the fear of 
losing foreign direct investment (FDI), China does not have 
strong incentives in using compulsory licenses (Huang, 2012).  
According to World Development Indicators & Global 
Development Finance 2010, the net flow of FDIs in China was 
more than eight times of that in India and twenty times of that 
in Thailand, respectively (The World Bank, 2012).  Attracting 
FDI, so far, holds more benefit for China than the costs of 
issuing compulsory licenses, as well as the risk of strong 
opposition from multinational companies and developed 
countries. 
Another reason why China has not issued any compulsory 
license for NCD treatment is to affirm its image of being 
committed to intellectual property right protections and 
standards, since joining the WTO in 2001.  China immediately 
launched domestic procedures to enforce TRIPS, and became 
one of the earliest members to accept the Protocol amending 
the TRIPS agreement after it joined the WTO (Huang, 2012). 
Moreover, in December 2011, China’s National Development 
& Reform Commission (NDRC) published the amended 
Industry Catalogue for Foreign Investments, which removed 
foreign investments in the pharmaceutical distribution 
business from the Restricted Category.  It also encouraged 
foreign pharmaceutical companies to localize the 
manufacturing of more novel vaccines in China (Sidley Austin 
LLP. 2012). The amendment subjected foreign pharmaceutical 
companies to less regulation. China also made further 
commitments to the protection of intellectual property rights 
during the 18th National Congress of the Communist Party of 
China in November 2011 (Hu. 2012). 
In March 2012, China amended its intellectual property laws 
in order to allow the government to issue compulsory licenses 
for local generics makers to produce and export patented drugs 
(Taylor, 2012). The inclusion of compulsory licenses in 
China’s legal system may lay the groundwork for China to 
further issue compulsory licenses for NCD drugs in the future, 
if the benefit of issuing compulsory license to address public 
health concerns outweighs the risks of losing foreign direct 
investment.  
 
D. Sub-Saharan Africa 
 
Sub-Saharan African countries are experiencing the double 
burden of communicable diseases and NCDs.  HIV/AIDs still 
remains the leading cause of deaths in Sub-Saharan Africa 
(Mathers, Boerma, Fat. 2009).  In 2005, the United Nations 
Programme on HIV/AIDS estimated that about 40 million 
people are currently infected with HIV, of whom about 25.8 
million, or 64 percent of the total, are in Sub-Saharan Africa 
(UNAIDS, WHO, 2005).  However, the epidemiological 
transition from predominantly communicable diseases to 
NCDs is already well underway in Sub-Saharan Africa.  In 
2004, 25% of all deaths in Sub-Saharan Africa were caused by 
NCDs.  It is estimated that by 2030, NCDs will cause 46% of 
all the deaths (WHO, 2012). 
Although there has been little application of TRIPS 
flexibilities on NCDs in Sub-Saharan Africa, several examples 
of its use on communicable diseases can provide insights and 
learning for further extrapolation to NCDs. The major way to 
use TRIPs flexibilities for Sub-Saharan Africa is to grant 
compulsory licenses within the national legal framework to 
manufacture locally or import generic drugs from other 
countries, due to the limited production capacity. For example, 
Mozambique and Zambia, respectively, issued compulsory 
licenses to local producers to manufacture antiretrovirals in 
2004, with royalties paid to the original patent holders 
(Zambia Ministry of Commerce, Trade and Industry, 2004; 
The Government of Mozambique, 2004). The Ministries of 
Health of Guinea and Eritrea, respectively, issued compulsory 
GSTF International Journal of Nursing and Health Care (JNHC) Vol.1 No.1, October 2013
8 © 2013 GSTF
 
licenses for importation on patents on drugs to treat HIV-
AIDS in 2005 (Eritrea Ministry of Health, 2005).  
NCDs first became prevalent in developed countries and are 
now spreading to the developing world at a faster pace. Thus, 
pharmaceutical companies in developed countries have had 
the opportunity to develop their NCD drugs and make them 
available to their target populations.  However, LMICs have 
not had the same opportunity, since their focus has 
traditionally remained on communicable diseases. Therefore, 
pharmaceutical companies in developed countries can 
exorbitantly price NCD drugs (Mattke, Haims, et al. 2011). 
For example, the prices of insulin for treating diabetes are 
higher in Africa than in the Eastern Mediterranean and South 
East Asia.  Even within the same region, the price of insulin 
by a producer ranged from US$ 9 in Zimbabwe to over US$ 
44 in Congo (Abegunde). This makes it crucial for middle-
income countries to make full use of TRIPS flexibilities 
because they can strengthen their domestic capacities to 
produce generic drugs and to be able to provide them at an 
affordable price to different income-based population 
segments in low-income countries. 
Groups that support strong pharmaceutical patent protection 
argue that patents are not the obstacles for access to essential 
NCD medicines in Sub-Saharan Africa. The World 
Intellectual Property Organization (WIPO) asserts that the real 
issue for access to NCD treatment is the inadequate financing 
of overall health systems and the severe lack of health care 
infrastructures, since most drug companies have not obtained 
patents widely in Africa (IIPI. 2000).  There is little doubt that 
the lack of access to essential medicines in Sub-Saharan 
Africa does not rest solely with patent protection, but also with 
non-patent problems such as poverty, the lack of supportive 
infrastructure, and poor governance (Zainol, Amin, et al. 
2011). However, with the NCD situation getting worse in this 
region, patented drugs will not only detract from current 
patient treatment, but also create a monopoly in the region’s 
market.  Such an event will be detrimental to their national 
capacity for addressing public health issues in the long run.     
IV. POLICY AND ADVOCACY RECOMMENDATIONS 
Based upon a combination of theoretical and practical 
factors related to TRIPS and the international discourse on the 
global NCD burden, the following are three major 
recommendations which address current barriers that make it 
difficult to make the case for using TRIPs framework for 
LMICs to be able to have access to essential NCD 
medications.   
1.) Extend the time frame for least developed countries 
(LDCs) to be able to use TRIPS flexibilities to 2025 
rather than 2016.  Also, allow this extended 
deadline for middle-income countries.   
Currently, the 2016 deadline is only for LDCs, but because 
of the groundwork and level of advocacy growing for NCD 
prevention and control, this deadline is not feasible.  Another 
issue that arises is that since there is not clear consensus as to 
what NCD drugs are affected by patent regulations just yet. 
This means middle-income countries need more time with 
pharmaceutical industry capacities to be able to also develop 
these drugs. To simply say that the HIV/AIDS case was a 
victory and then ignore the alarming rate of NCD mortality 
and lack of treatment in LMICs would be contradictory to the 
goals of TRIPS and the Doha Declaration on Public Health. 
The rationale for the 2025 deadline is that it would 
streamline the goals of TRIPS, the Doha Declaration on Public 
Health, and the processes discussed at the NCD UN High 
Level Meeting of 2011.  One of these processes is creating a 
goal of achieving universal targets for NCD reduction on the 
mortality, exposure, and health systems levels by 2025.  
Although these targets have not been finalized, they will be a 
tangible way of gauging the urgency and the time needed to be 
able to ensure access to NCD essential medicines, which is a 
part of the health systems targets. 
2.) Explore differential pricing alternatives to 
compulsory licenses as a bargaining chip for 
middle-income countries. 
Differential pricing, as discussed earlier, allows for prices to 
be charged to different countries based on income and poverty 
levels.  As previously discussed, the major concern for 
pharmaceutical companies is that profit margins in high and 
middle-income markets and high distribution channel markups 
in low-income countries could dilute the benefits of 
differential pricing to poor patients.  However, this is slowly 
changing because with economic and demographic growth in 
low- and middle-income markets the potential market size of 
many LMICs is greater. This trend is so significant that 
ignoring it would not be feasible in the long run given the 
amount of international pressure put on companies to be more 
socially responsible, and more importantly the growth of 
emerging markets for generic pharmaceutical manufacturing.   
What this means is essentially a compromise and win-win 
situation both for social good and the business goals of 
pharmaceutical companies (Yadav, 2010).  While it is not in 
the scope of this paper to discuss all models, pharmaceutical 
companies would have to, in the end, be innovative in creating 
the right strategies and fairly assessing risks based upon the 
markets they are trying to reach.  This was illustrated in the 
earlier example of Novartis’ method of intra-country pricing 
for the drug Coartem (see section II).  Of course, in low-
income countries, differential pricing alone cannot be 
successful.  There would need to be, in this case, some public-
private collaboration in which some government subsidies 
keep the drugs at a low cost in order for differential pricing to 
work at its best (Yadav, 2010).  
3.) Make efficient use of bilateral and multilateral 
trade agreements in a way that is coherent with 
TRIPS flexibilities for better medication access. 
With this recommendation low-income countries which 
lack NCD drug production capacity, even in generic form, can 
collaborate with middle-income countries to achieve the much 
needed drugs that are typically very cost prohibitive.  This 
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would mean, to some degree LMICs need to be wary of the 
free trade agreements that fall under TRIPS Plus, which would 
hinder, as discussed earlier, not only access to NCD essential 
medicines, but also the growth of foreign direct investments.  
Instead, developing countries should utilize Preferential Trade 
Agreements (PTA) for deeper integration. Although the 
participation of developing countries, including LDCs, have 
increased significantly, the scope of PTAs needs to be further 
extended to address public policy concerns, such as public 
health (WTO, 2011). Developing countries can make use of 
PTAs with developed countries to include preferential trade on 
NCD essential medicines.  This could reduce prices and 
eliminate tariffs on advanced technologies in order to 
strengthen domestic manufacturing capacity for NCD 
treatment. LDCs should also utilize the South-South 
agreement to import cheaper NCD drugs from middle-income 
countries such as India, China and Brazil.     
However, policy makers in developing countries should be 
aware that some PTAs, especially with the US and European 
countries, include agreements on a more strict intellectual 
property rights protection regime, which can go beyond the 
TRIPS minimum standards. For instance, the US Trade 
Promotion Authority Act of 2002 stipulates that provisions of 
any trade agreement should be ‘a standard of protection 
similar to that found in US law’, including the full 
implementation of the TRIPS obligations (Trade Act of 2002). 
Developing countries need to balance the benefits and 
potential risks under PTAs, realizing the complexities of these 
agreements. In the case of the agreements with the US, 
countries should be careful about the stringent monitoring 
processes by the United States Trade Representative (USTR) 
through the 301 annual reviews (Roffe, Spennemann. 2012). 
In the end, the opening up of further discussion in 
addressing NCD problems can be enhanced by keeping up 
with specific targets for reducing NCD mortality rates and 
drugs, as prescribed by the World Health Organization.  
Allowing imports and exports of generic drugs for affordable 
NCD treatment in poor nations could also be useful.  Opening 
up further discussion on import and export of generic drugs 
does not necessarily mean that the definition of ‘public health 
emergency’ should be made specific, as that could hurt the 
cause and process of increasing access to NCD medications.   
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